Personalis (NASDAQ:PSNL) Downgraded to “Sell” Rating by Wall Street Zen

Personalis (NASDAQ:PSNL) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

PSNL has been the topic of several other research reports. Morgan Stanley boosted their price target on shares of Personalis from $9.00 to $11.00 and gave the company an “equal weight” rating in a research report on Monday, December 1st. Lake Street Capital reissued a “buy” rating and issued a $11.00 price target on shares of Personalis in a research note on Wednesday, November 5th. HC Wainwright raised their price target on shares of Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Guggenheim upped their price objective on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a report on Monday, January 26th. Finally, Needham & Company LLC increased their price objective on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Personalis presently has an average rating of “Moderate Buy” and an average price target of $11.14.

Personalis Price Performance

PSNL stock opened at $9.06 on Friday. Personalis has a 1 year low of $2.83 and a 1 year high of $11.50. The firm has a market capitalization of $804.53 million, a PE ratio of -9.96 and a beta of 1.98. The business has a 50 day simple moving average of $8.83 and a 200-day simple moving average of $7.96.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.05. The firm had revenue of $17.35 million for the quarter, compared to the consensus estimate of $17.12 million. Personalis had a negative return on equity of 42.81% and a negative net margin of 116.69%. On average, equities research analysts expect that Personalis will post -1.4 EPS for the current year.

Institutional Trading of Personalis

Several institutional investors have recently added to or reduced their stakes in PSNL. International Assets Investment Management LLC purchased a new stake in Personalis in the fourth quarter valued at approximately $31,000. Legal & General Group Plc acquired a new stake in shares of Personalis in the second quarter valued at $30,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Personalis in the 2nd quarter valued at $34,000. Caitong International Asset Management Co. Ltd lifted its stake in Personalis by 184.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,536 shares of the company’s stock worth $44,000 after acquiring an additional 3,592 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after acquiring an additional 5,177 shares during the period. Institutional investors and hedge funds own 61.91% of the company’s stock.

Key Stories Impacting Personalis

Here are the key news stories impacting Personalis this week:

• Positive Sentiment: Analyst price-target upgrade — Needham raised its PSNL target from $10 to $12 and reiterated a “buy” rating, implying meaningful upside from the current price and signaling increased analyst confidence. Benzinga
• Positive Sentiment: Operational growth target — Management outlined a plan targeting ~170% clinical test-volume growth for 2026 and highlighted acceleration from reimbursement and its MRD (minimal residual disease) strategy, which, if realized, would drive revenue and margin scaling. Seeking Alpha: Clinical Test Volume Growth
• Positive Sentiment: Q4 outperformance vs. EPS estimates — Personalis reported a $0.26 loss per share, beating consensus by $0.05, and delivered revenue roughly in line to slightly above expectations, which supports the near-term stock uplift. Press Release / Q4 Results
• Neutral Sentiment: Earnings call and transcript available — Management commentary and the full Q4 2025 call transcript provide more color on reimbursement progress, MRD commercialization cadence and margin plans; these details will determine whether the growth targets are credible. Yahoo Finance: Q4 Earnings Call Transcript
• Neutral Sentiment: Media coverage / snapshot pieces summarize results and strategy but add little new detail beyond the company release and call. SeattlePI: Q4 Snapshot
• Negative Sentiment: FY2026 revenue guidance set below street expectations — Personalis guided to roughly $78–$80M for FY2026 versus a consensus near $81M, introducing downside risk to near-term estimates and valuation. Yahoo Finance: Full Year Results & Guidance
• Negative Sentiment: Elevated short interest and persistent losses — Short interest rose ~21% in February to ~12.5% of float (an 8.6-day ratio), while the company remains unprofitable with negative margins and ROE, increasing volatility and downside risk if execution slips. MarketBeat: Short Interest & Stock Data
• Negative Sentiment: Conflicting coverage on revenue beat/miss — Some outlets flagged a revenue miss while company/other reports show a slight revenue beat; this mixed narrative can amplify intraday moves as investors parse which data source is authoritative. Zacks: Q4 Loss / Revenue Comment

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.